Navigation Links
New Phase IV Clinical Study Indicates LidoSite Provides,Rheumatology Patients Superior Pain Relief

FAIR LAWN, N.J.--(BUSINESS WIRE)--Mar 19, 2007 - Vyteris Holdings (Nevada), Inc. (OTCBB: VYHN), today announced results from a new phase IV "Open Label" clinical study demonstrating that LidoSite, the first FDA approved active patch for dermal analgesia, provided better pain relief to more than 73 percent of patients receiving injections of hyaluronic acid during treatment for osteoarthritis than usual topical analgesics.

"Treatment can be very painful, requiring multiple injections into sensitive joints, with many patients having a difficult time with this pain, leading some to avoid regular treatment," said Dr. Evan Liebowitz, a rheumatologist affiliated with Prospect Medical Office in Midland Park, NJ and Valley Hospital in Ridgewood, NJ. "Patients who avoid regular treatments for rheumatoid arthritis and osteoarthritis risk further loss of articular cartilage in the knee."

The study, involving six study sites and 14 physicians, followed 63 patients over the course of two routine injections of hyaluronic acid for the treatment of osteoarthritis.

During the first treatment, patients either received no local anesthesia or an alternate local anesthesia prior to cannulation or needle puncture. During the second treatment, patients received the LidoSite system, comprised of the LidoSite Patch and the LidoSite Controller. In the study more than 73 percent preferred LidoSite to the treatment used during their first visit. Additionally, the majority of rheumatology physicians surveyed were satisfied with LidoSite, compared to other available treatment options, such as ethyl chloride, lidocaine injections or fluormethane spray.

"This initial study demonstrates the acceptability among patients and rheumatologists for using LidoSite as an effective treatment regime for needle pain for the multiple injections arthritis requires, as well as its potential availability in the doctor's office setting."
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/3/2015)... India , July 4, 2015 ... continue cible les épidémies que sont l,hypertension, le ... et du Sud-Est, par l,intermédiaire de plateformes éducatives ... maladies.      (Photo: http://photos.prnewswire.com/prnh/20150630/227090 ... en charge le diabète en ligne , ...
(Date:7/3/2015)... 3, 2015 Der ... bestimmter Abschlussbedingungen eine 100-prozentige Beteiligung am Unternehmen ... Mit dieser Übernahme dringt Lupin in den ... von 765 Mrd. RUB im Jahr 2014 ... gehörte (IMS Health). Seit über einem Jahrzehnt ...
(Date:7/2/2015)... HILL, N.C. , July 2, 2015 /PRNewswire/ ... own employees to capture critical product and market ... are many benefits to employee-based studies, it is ... leverage their own internal employees to capture critical ... study by benchmarking firm, Best Practices, LLC, most ...
Breaking Medicine Technology:Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 3Lupin übernimmt Biocom aus Russland 2Lupin übernimmt Biocom aus Russland 3Leveraging Employee Insights to Produce Cutting-Edge Market Research 2
... Sept. 26 Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ... Biosciences, Inc. (Ibis), has been awarded a subcontract,of ... aid in influenza,surveillance research through application of the ... jointly by Ibis and the Lovelace,Respiratory Research Institute ...
... Visiting Nurse Associations of America, Families Fighting Flu and The, Clorox ... ... Less Scary, WASHINGTON, Sept. 25 A new report by the,Centers ... children who need to get a flu vaccination actually get,one, despite the ...
Cached Medicine Technology:Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies 2Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies 3Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies 4Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies 5Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Don't Vaccinate 2Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Don't Vaccinate 3Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Don't Vaccinate 4Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Don't Vaccinate 5
(Date:7/3/2015)... ... July 03, 2015 , ... ... on June 25, 2015 at 1:00pm. The Association welcomed speaker C. Daniel McGillicuddy ... injured bicyclists and practical points of investigating these types of cases. , Each ...
(Date:7/3/2015)... ... 03, 2015 , ... Jennifer Renee Hanes, DO is the new Medical Director ... network of independent freestanding emergency rooms in the United States. , “We are excited ... facility,” said Executive Medical Director of First Choice Emergency Room, Dr. James M. Muzzarelli. ...
(Date:7/3/2015)... ... 03, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... will reveal biblical truth and expose popular lies regarding proper relationships according to the ... Sex”, immediately goes into the core of the subject by explaining why certain types ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... sweetFrog Enterprises, ... Mississippi. The opening is the first sweetFrog store located in Mississippi. The premium frozen ... companies in 2014. , The store, located at 104 Railroad Avenue, New Albany, MS ...
(Date:7/2/2015)... ... July 02, 2015 , ... Following the recent report by JAMA ... Americans outnumber merely overweight Americans, Samir Becic emphatically declared a war on obesity in ... right now," Becic said. "We must understand the magnitude of this discovery. For that ...
Breaking Medicine News(10 mins):Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:sweetfrog Opens First Location in Mississippi 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4
... A study published in the October 15 issue ... the Cleveland Adolescent Sleepiness Questionnaire (CASQ), a new self-completed ... The study, led by James C. Spilsbury, PhD, of ... Ohio, focused on a subsample of 411 adolescents between ...
... 11:30 am EDT, TEL AVIV, Israel, October 15 ... that it has signed,an agreement to acquire 100% of ... Blessing Biotech GmbH (together the "Gewurzmuller,Group"), in consideration for ... The Company will be hosting a conference call ...
... Island Hospital and Brown University researchers reported that 18 percent ... initial psychiatric clearance for the surgery. The study is the ... for surgery, and the largest to determine the percentage of ... exclusion. It was published in the October edition of the ...
... of ills such as heart disease , , SUNDAY, ... collections of genetic and clinical data available free to ... Institutes of Health. , The Web-based SHARe (SNP Health ... from a number of large population-based studies, starting with ...
... breathing disorder, arterial trouble , FRIDAY, Oct. 12 (HealthDay ... airway pressure (CPAP) to treat people with obstructive sleep ... of the arteries -- within months, a new study ... of a direct link between obstructive sleep apnea and ...
... BEACH, Calif., Oct. 12 History,will be written if ... Act during a vote scheduled for next week. It ... law regarding swimming pool and spa safety.,The National Drowning ... but with wording similar to HR 1721 passed on ...
Cached Medicine News:Health News:New tool to assess excessive daytime sleepiness in adolescents published in JCSM 2Health News:Frutarom Gewurzmuller and Blessing Biotech Acquisition Conference Call Scheduled for Monday, October 15, 2007 2Health News:1 in 5 bariatric surgery candidates not psychologically cleared for surgery 2Health News:U.S. Unveils Database of Genetic, Clinical Research 2Health News:Sleep Apnea Treatment Helps Stave Off Heart Disease 2Health News:NDPA Urges Passage of Historic Pool Bill 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: